Notícias Eli Lilly and Co - LLY | Ações New York Stock Exchange | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

Início
Investir
Ações
EUA
NYSE
Eli Lilly and Co (LLY)
Eli Lilly and Co (LLY) Notícias

Eli Lilly and Co (LLY)

929,72

18,66

(2,05%)

Fechado 06 Março 6:00PM

Atrasado por 15 minutos

928,53

-1,19

(-0,13%)

Após o horário de negociação: 9:55PM

Atrasado por 15 minutos

Seu centro para cotações em tempo real, discussões ao vivo e novas ideias.

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Lilly to participate in Leerink Partners Global Healthcare Conference

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor

Form 4 - Statement of changes in beneficial ownership of securities

Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company

Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições